Acquisition of Antibody Against Cytomegalovirus After Kidney Transplantation in Seronegative Recipients

Ishikawa, Shoko; Tasaki, Masayuki; Saito, Kazuhide; Nakagawa, Yuki; Ikeda, Masahiro; Takahashi, Kota; Tomita, Yoshihiko

doi:10.1016/j.transproceed.2023.03.007

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, 82.1% (156/190) and 86.1% of the recipients were CMV seropositive before KTx and at 1 year post KTx (the start of this study), respectively. This is a common situation in the current era ( Ishikawa et al., 2023 ). As we showed in the present study, CMV serostatus before KTx may not be a significant factor predisposing to CMV infection in the chronic phase.…”

Section: Discussionmentioning

confidence: 99%

Long-term CMV monitoring and chronic rejection in renal transplant recipients

Ishikawa

Tasaki

Saito

et al. 2023

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

IntroductionCytomegalovirus (CMV) is well established to be an independent risk factor for graft loss after kidney transplantation (KTx). Monitoring for CMV in the chronic phase is not defined in the current guideline. The effects of CMV infection, including asymptomatic CMV viremia, in the chronic phase are unclear.MethodsWe performed a single-center retrospective study to investigate incidence of CMV infection in the chronic phase, defined as more than 1 year after KTx. We included 205 patients who received KTx between April 2004 and December 2017. The CMV pp65 antigenemia assays to detect CMV viremia were continuously performed every 1–3 months.ResultsThe median duration of the follow-up was 80.6 (13.1–172.1) months. Asymptomatic CMV infection and CMV disease were observed in 30.7% and 2.9% in the chronic phase, respectively. We found that 10–20% of patients had CMV infections in each year after KTx which did not change over 10 years. The history of CMV infection in the early phase (within 1 year after KTx) and chronic rejection were significantly associated with CMV viremia in the chronic phase. CMV viremia in the chronic phase was significantly associated with graft loss.DiscussionThis is the first study to examine the incidence of CMV viremia for 10 years post KTx. Preventing latent CMV infection may decrease chronic rejection and graft loss after KTx.

show abstract

Section: Discussionmentioning

confidence: 99%